Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
Launched by NOVARTIS PHARMACEUTICALS · Mar 2, 2012
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients hospitalized or requiring admission to hospital for management of acute heart failure within the previous 48 hours.
- • Pulmonary wedge pressure above or equal to18 mmHg determined by right heart catheterization
- Exclusion Criteria:
- • Systolic blood pressure below 115 mmHg
- • Significant valvular diseases or arrythmias
- • Acute coronary syndrome in previous 45 days
- • Treatment with mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device)
- • Impaired renal or hepatic function
- • Other protocol-defined inclusion/exclusion criteria may apply
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Halle/'Saale, , Germany
Groningen, , Netherlands
Moscow, , Russian Federation
Bad Nauheim, , Germany
Brescia, Bs, Italy
Caba, Buenos Aires, Argentina
Dortmund, , Germany
Warszawa, , Poland
Wroclaw, , Poland
Greifswald, , Germany
S. Petersburg, , Russian Federation
Saint Petersburg, , Russian Federation
Kemerovo, , Russian Federation
Erfurt, , Germany
Tomsk, , Russian Federation
Buenos Aires, , Argentina
St Petersburg, , Russian Federation
St. Petersburg, , Russian Federation
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials